Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Up to 30,000 lives could be saved over the next decade thanks to a proposed pioneering government collaboration with pharmaceutical company Novartis to tackle heart disease – a leading cause of death in the UK.

© Shutterstock

The yet to be approved drug inclisiran, a treatment to lower cholesterol, will be studied in UK patients as part of a large-scale NHS clinical trial expected to start later this year. Additionally in a world-first, the drug is expected to be available through a population-level agreement – pioneering a game-changing approach to reducing the risk of heart disease.

Early results from clinical trials suggest that if inclisiran is given to 300,000 patients annually, it could help prevent 55,000 heart attacks and strokes, and has the potential of saving 30,000 lives in the next 10 years.

Heart disease is the world’s biggest killer and the second biggest cause of death in the UK, with over three million people suffering from atherosclerotic cardiovascular disease and two and a half million currently relying on statins to lower their cholesterol. Recent trials have shown inclisiran can halve bad cholesterol in just two weeks.

Inclisiran, a bi-annual injection, is expected to be filed for approval as a preventative add-on treatment to statins for patients who have already been diagnosed with cardiovascular disease later this year.

Read more (University of Oxford website)

Similar stories

Nicola Smart to deliver John French Lecture

The British Atherosclerosis Society's John French Memorial Lecture is named in honour of the Oxford-based pathologist, Dr John French, who made seminal observations and contributions to the field of cardiovascular pathology.

Having a healthier heart associated with better problem-solving and reaction time

People with healthier heart structure and function appear to have better cognitive abilities, including increased capacity to solve logic problems and faster reaction times, according to a study involving University of Oxford and Queen Mary University of London (QMUL) researchers.

Study provides new insights into causal mechanisms for atrial fibrillation

A large-scale genetic study, led by Oxford BHF researchers Dr Parag Gajendragadkar, clinical DPhil student, Professor Barbara Casadei and Professor Jemma Hopewell, has shed new light on common heart rhythm disturbances

Travels with Vignesh

Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.